Evidence map›Paper›PMID 41546036›Full record

ArticleBMC biology2026

BRD4-mediated transcriptional activation of PDLIM4 enhances p21 stability and chemosensitivity in lung adenocarcinoma independent of p53.

Qingwei Wang, Liangsheng Guo, Shuai Wang, Chengdan Guan, Junhao Pan, Shaoping Zhu, Lei Zheng, Xuehua Wu, Yonghui Gu, Tao Shu and 3 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in BMC biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Qingwei Wang *Zhanjiang Key Laboratory of Hepatobiliary-Related Diseases, The Affiliated Hospital of Guangdong Medical University, Zhanjiang, 524023, China.
Liangsheng Guo *Institute of Respiratory Diseases, The Affiliated Hospital of Guangdong Medical University, Zhanjiang, 524023, China.
Shuai Wang *Institute of Respiratory Diseases, The Affiliated Hospital of Guangdong Medical University, Zhanjiang, 524023, China.
Chengdan Guan *Institute of Respiratory Diseases, The Affiliated Hospital of Guangdong Medical University, Zhanjiang, 524023, China.
Junhao PanZhanjiang Key Laboratory of Hepatobiliary-Related Diseases, The Affiliated Hospital of Guangdong Medical University, Zhanjiang, 524023, China.
Shaoping ZhuInstitute of Laboratory Animal Center, Guangdong Medical University, Zhanjiang, 524023, China.
Lei ZhengInstitute of Respiratory Diseases, The Affiliated Hospital of Guangdong Medical University, Zhanjiang, 524023, China.
Xuehua WuInstitute of Respiratory Diseases, The Affiliated Hospital of Guangdong Medical University, Zhanjiang, 524023, China.
Yonghui GuZhanjiang Key Laboratory of Hepatobiliary-Related Diseases, The Affiliated Hospital of Guangdong Medical University, Zhanjiang, 524023, China.
Tao ShuZhanjiang Key Laboratory of Hepatobiliary-Related Diseases, The Affiliated Hospital of Guangdong Medical University, Zhanjiang, 524023, China.
Lianxiang LuoThe Marine Biomedical Research Institute of Guangdong Zhanjiang, School of Ocean and Tropical Medicine, Guangdong Medical University, Guangdong, 524023, China.
Tianwen LaiDepartment of Respiratory and Critical Care Medicine, Key Laboratory of Immune Inflammation and Metabolism, The First Dongguan Affiliated Hospital, Guangdong Medical University, Dongguan, 523710, China.
Xiao GaoInstitute of Respiratory Diseases, The Affiliated Hospital of Guangdong Medical University, Zhanjiang, 524023, China. gaoxiao@gdmu.edu.cn.

Funding

Basic and Applied Basic Research Foundation of Guangdong Province 2023A1515012298National Natural Science Foundation of China 81903244National Natural Science Foundation of China 82103126
6 · The paper itself

Abstract

backgroundUnderstanding p53-independent regulatory mechanisms is crucial for predicting outcomes in lung adenocarcinoma (LUAD) and developing improved therapeutic strategies.

resultsWe found that PDLIM4 is highly expressed in LUAD tumor tissues, where it induces G2/M phase cell cycle arrest and suppresses cell proliferation, suggesting its potential role in improving patient prognosis. Our study identified BRD4, a bromodomain and extraterminal (BET) family protein, as a key transcriptional regulator of PDLIM4, acting through its BD1 domain. Further analysis revealed that wild-type PDLIM4 stabilizes p21 by blocking its RNA degradation, leading to p21 protein accumulation and subsequent inhibition of cell proliferation. In contrast, the S116 mutation in PDLIM4 abrogates this regulatory effect. Notably, activation of the BRD4/PDLIM4/p21 pathway enhanced chemosensitivity to doxorubicin in both LUAD cells and xenograft tumor models.

conclusionsGiven the high mutation frequency of PDLIM4 recorded in the TCGA cancer database, our findings reveal a critical regulatory signaling pathway that suppresses LUAD progression and augments chemotherapy efficacy.

Indexed as

Adenocarcinoma of LungCell Cycle ProteinsCyclin-Dependent Kinase Inhibitor p21LIM Domain ProteinsLung NeoplasmsTranscriptional ActivationTranscription FactorsAnimalsBromodomain Containing ProteinsCell Line, TumorGene Expression Regulation, NeoplasticHumansMiceTumor Suppressor Protein p53BRD4 protein, humanBromodomain Containing ProteinsCDKN1A protein, humanCell Cycle ProteinsCyclin-Dependent Kinase Inhibitor p21LIM Domain ProteinsTP53 protein, humanTranscription FactorsTumor Suppressor Protein p53BRD4Lung adenocarcinomaP21P53 independentPDLIM4

Identifiers

PMID41546036
PMCPMC12896191

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.